

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 20992

Title: Roles of lipoprotein receptors in the entry of hepatitis C virus

Reviewer's code: 00012386

Reviewer's country: Japan

Science editor: Ya-Juan Ma

Date sent for review: 2015-06-29 23:01

Date reviewed: 2015-07-03 08:06

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

1) In Core Tip, Make a correction from "hepatocarcinoma" to "hepatocellular carcinoma". 2) In Introduction section, Authors described that "Different from hepatitis A virus and hepatitis B virus, there is no available vaccine against HCV until now, and current therapy for HCV infection is based on a combination of interferon-alpha and ribavirin[3]." Now, standard of care for HCV is DAAs with or without peginterferon plus ribavirin. See the references as follows: (1) Kanda T, Yokosuka O, Omata M. Treatment of hepatitis C virus infection in the future. Clin Transl Med. 2013 Apr 11;2(1):9. doi: 10.1186/2001-1326-2-9. PMID: 23577631 (2) Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010 Aug 19;4(3):548-61. doi: 10.1007/s12072-010-9193-3. PMID: 21063477 3) About Ref.[5], authors should also add the original references as follows: (1) Meyer K, Basu A, Przysiecki CT, Lagging LM, Di Bisceglie AM, Conley AJ, Ray R. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol. 2002 Mar;76(5):2150-8. PMID: 11836392 (2) Lagging LM, Meyer K, Westin J, Wejst R, Norkrans G, Lindh M, Ray R. Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients. J Infect Dis.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

2002 Apr 15;185(8):1165-9. Epub 2002 Apr 1. PMID: 11930327 4) Authors described LDLR, SRBI and CD81 as HCV receptors. How was Claudin-1, occluding or other? Authors should describe them in HCV infection section.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 20992

Title: Roles of lipoprotein receptors in the entry of hepatitis C virus

Reviewer's code: 00012216

Reviewer's country: Spain

Science editor: Ya-Juan Ma

Date sent for review: 2015-06-29 23:01

Date reviewed: 2015-07-07 00:58

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Lyu et al. carry out a review about HCV entry into the host's cells, focusing on the role of lipoprotein receptors. First of all, authors give a general description of HCV entry steps, but in a lower depth than a recent WJG paper (World J Gastroenterol 2014; 20(13): 3457-3467). Later, they focus on SR-BI and LDLR where authors make a deeper review. The manuscript could improve by adding a graph describing HCV entry steps and a table showing the main features of SR-BI and LDLR. The last part is difficult to understand in the review, since the title is about the role of lipoproteins in HCV entry, but in the last item authors review immunological aspects that could be suitable for a different manuscript. So, from my point of view it is not clear the manuscript's structure, since it is not about the whole HCV entry process, but only about the role of lipoprotein receptors. Nevertheless, authors discuss about CD81, DC-SIGN, L-SIGN, which could make sense as an introduction, but then why not comment about CLDN1, OCLN, EGFR, EphA2, Tfr1 or NPC1L1. In any case, the last part of the review (immunology aspects) does not follow any logic, according to the subject of the review. Finally, authors comment that the current standard of care for HCV is IFN+RBV, but nowadays the standard treatment consists of direct acting antivirals. Authors could also add some information



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

about the role of blocking the lipoprotein receptors as a potential therapeutic target.